贝伐珠单抗与GC化疗方案联合治疗晚期非小细胞肺癌的效果及药物经济学评价

Efficacy and Pharmacoeconomic Evaluation of Bevacizumab Combined with GC Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

目的 探究贝伐珠单抗联合GC化疗方案(顺铂+吉西他滨)治疗晚期非小细胞肺癌(NSCLC)的效果及药物经济学价值。方法 选取2020年7月—2022年7月收治的86例晚期NSCLC,依据治疗方案分为对照组和观察组,每组43例。对照组给予GC化疗方案,观察组给予贝伐珠单抗联合GC化疗方案。对比2组疗效、毒副反应发生情况以及治疗前后血生化指标,并进行成本-效果分析。结果 观察组客观缓解率58.14%(25/43)、疾病控制率93.02%(40/43)均高于对照组的32.56%(14/43)、72.09%(31/43)(P<0.05)。治疗2、4个疗程,观察组血清癌胚抗原、糖类抗原125、神经元特异性烯醇化酶、血管内皮生长因子、碱性成纤维细胞生长因子均低于对照组(P<0.05)。2组各项毒副反应总发生率比较无显著差异(P>0.05)。观察组总成本高于对照组(P<0.05)。观察组成本-效果比为790.67低于对照组的901.31,且敏感性分析显示,成本-效果分析稳定可靠。结论 贝伐珠单抗联合GC化疗方案治疗晚期NSCLC患者,可下调肿瘤标志物及血管内皮因子水平,提升疗效,且成本-效果优势明显。

Objective To explore the efficacy and pharmacoeconomic value of Bevacizumab combined with GC chemotherapy regimen(Cisplatin+Gemcitabine) in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 86 patients with advanced NSCLC treated from July 2020 to July 2022 were selected and divided into control group(n=43) and observation group(n=43) according to treatment plan.The control group was given GC chemotherapy,and the observation group was given Bevacizumab combined with GC chemotherapy.The efficacy,occurrence of toxic and side effects and blood biochemical indexes before and after treatment were compared between the two groups,and cost-effectiveness analysis was performed.Results The objective remission rate of 58.14%(25/43) and disease control rate of 93.02%(40/43) in the observation group were higher than those in the control group [32.56%(14/43) and 72.09%(31/43)](P<0.05).After 2 and 4 courses of treatment,the serum carcinoembryonic antigen,carbohydrate antigen 125,neuron specific enolase,vascular endothelial growth factor and basic fibroblast growth factor in observation group were lower than those in control group(P<0.05).There was no significant difference in the total incidence of toxic and side effects between the two groups(P>0.05).The total cost of observation group was higher than that of control group(P<0.05).The cost-effectiveness ratio(790.67) was lower than that of the control group(901.31),and sensitivity analysis showed that cost-effectiveness analysis was stable and reliable.Conclusion In the treatment of advanced NSCLC patients,Bevacizumab combined with GC chemotherapy can downregulate the levels of tumor markers and vascular endothelial factors,and improve the efficacy,with obvious cost-effectiveness advantage.